Literature DB >> 27037276

A novel in vitro platform for the study of SN38-induced mucosal damage and the development of Toll-like receptor 4-targeted therapeutic options.

Hannah R Wardill1, Rachel J Gibson2, Ysabella Za Van Sebille3, Kate R Secombe3, Richard M Logan4, Joanne M Bowen3.   

Abstract

Tight junction and epithelial barrier disruption is a common trait of many gastrointestinal pathologies, including chemotherapy-induced gut toxicity. Currently, there are no validated in vitro models suitable for the study of chemotherapy-induced mucosal damage that allow paralleled functional and structural analyses of tight junction integrity. We therefore aimed to determine if a transparent, polyester membrane insert supports a polarized T84 monolayer with the phenotypically normal tight junctions. T84 cells (passage 5-15) were seeded into either 0.6 cm(2), 0.4 µm pore mixed-cellulose transwell hanging inserts or 1.12 cm(2), 0.4 µm pore polyester transwell inserts at varying densities. Transepithelial electrical resistance was measured daily to assess barrier formation. Immunofluoresence for key tight junction proteins (occludin, zonular occludens-1, claudin-1) and transmission electron microscopy were performed to assess tight junction integrity, organelle distribution, and polarity. Reverse transcription-polymerase chain reaction was performed to determine expression of toll-like receptor 4 (TLR4). Liquid chromatography was also conducted to assess SN38 degradation in this model. Polyester membrane inserts support a polarized T84 phenotype with functional tight junctions in vitro. Transmission electron microscopy indicated polarity, with apico-laterally located tight junctions. Immunofluorescence showed membranous staining for all tight junction proteins. No internalization was evident. T84 cells expressed TLR4, although this was significantly lower than levels seen in HT29 cells (P = .0377). SN38 underwent more rapid degradation in the presence of cells (-76.04 ± 1.86%) compared to blank membrane (-48.39 ± 4.01%), indicating metabolic processes. Polyester membrane inserts provide a novel platform for paralleled functional and structural analysis of tight junction integrity in T84 monolayers. T84 cells exhibit the unique ability to metabolize SN38 as well as expressing TLR4, making this an excellent platform to study clinically relevant therapeutic interventions for SN38-induced mucosal damage by targeting TLR4.
© 2016 by the Society for Experimental Biology and Medicine.

Entities:  

Keywords:  In vitro model; SN38; barrier function; tight junctions; toll-like receptor 4; transwell support

Mesh:

Substances:

Year:  2016        PMID: 27037276      PMCID: PMC4994924          DOI: 10.1177/1535370216640932

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  30 in total

Review 1.  The tight junction in inflammatory disease: communication breakdown.

Authors:  Karen L Edelblum; Jerrold R Turner
Journal:  Curr Opin Pharmacol       Date:  2009-07-24       Impact factor: 5.547

2.  Studying permeability in a commonly used epithelial cell line: T84 intestinal epithelial cells.

Authors:  Rino P Donato; Adaweyah El-Merhibi; Batjargal Gundsambuu; Kai Yan Mak; Emma R Formosa; Xian Wang; Catherine A Abbott; Barry C Powell
Journal:  Methods Mol Biol       Date:  2011

Review 3.  Chemotherapy-induced gut toxicity: are alterations to intestinal tight junctions pivotal?

Authors:  Hannah R Wardill; Joanne M Bowen; Rachel J Gibson
Journal:  Cancer Chemother Pharmacol       Date:  2012-09-30       Impact factor: 3.333

4.  Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines.

Authors:  Arabelle Pfrunder; Heike Gutmann; Christoph Beglinger; Jürgen Drewe
Journal:  J Pharm Pharmacol       Date:  2003-01       Impact factor: 3.765

5.  LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis.

Authors:  Rich Y C Hsu; Carlos H F Chan; Jonathan D Spicer; Mathieu C Rousseau; Betty Giannias; Simon Rousseau; Lorenzo E Ferri
Journal:  Cancer Res       Date:  2011-03-01       Impact factor: 12.701

6.  VEGI attenuates the inflammatory injury and disruption of blood-brain barrier partly by suppressing the TLR4/NF-κB signaling pathway in experimental traumatic brain injury.

Authors:  Weiwei Gao; Zilong Zhao; Gongjie Yu; Ziwei Zhou; Yuan Zhou; Tingting Hu; Rongcai Jiang; Jianning Zhang
Journal:  Brain Res       Date:  2015-06-12       Impact factor: 3.252

7.  Establishment of a single-dose irinotecan model of gastrointestinal mucositis.

Authors:  Rachel J Gibson; Joanne M Bowen; Enrique Alvarez; John Finnie; Dorothy M K Keefe
Journal:  Chemotherapy       Date:  2007-08-21       Impact factor: 2.544

8.  Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice.

Authors:  Silvia H S P Pedroso; Angélica T Vieira; Rafael W Bastos; Jamil S Oliveira; Christiane T Cartelle; Rosa M E Arantes; Pedro M G Soares; Simone V Generoso; Valbert N Cardoso; Mauro M Teixeira; Jacques R Nicoli; Flaviano S Martins
Journal:  Microbiology       Date:  2015-07-28       Impact factor: 2.777

Review 9.  Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38.

Authors:  Vaskor Bala; Shasha Rao; Ben J Boyd; Clive A Prestidge
Journal:  J Control Release       Date:  2013-08-06       Impact factor: 9.776

10.  Tight junction defects are seen in the buccal mucosa of patients receiving standard dose chemotherapy for cancer.

Authors:  Hannah R Wardill; Richard M Logan; Joanne M Bowen; Ysabella Z A Van Sebille; Rachel J Gibson
Journal:  Support Care Cancer       Date:  2015-10-06       Impact factor: 3.603

View more
  4 in total

1.  Use of zebrafish to model chemotherapy and targeted therapy gastrointestinal toxicity.

Authors:  Ysabella Za Van Sebille; Rachel J Gibson; Hannah R Wardill; Thomas J Carney; Joanne M Bowen
Journal:  Exp Biol Med (Maywood)       Date:  2019-06-11

2.  Orally Deliverable Nanotherapeutics for the Synergistic Treatment of Colitis-Associated Colorectal Cancer.

Authors:  Weidong Han; Binbin Xie; Yiran Li; Linlin Shi; Jianqin Wan; Xiaona Chen; Hangxiang Wang
Journal:  Theranostics       Date:  2019-10-12       Impact factor: 11.556

3.  Knockdown of TRIM9 attenuates irinotecan‑induced intestinal mucositis in IEC‑6 cells by regulating DUSP6 expression via the P38 pathway.

Authors:  Wenjun Zhao; Qingming Wang
Journal:  Mol Med Rep       Date:  2021-10-22       Impact factor: 2.952

4.  Combined pharmacological administration of AQP1 ion channel blocker AqB011 and water channel blocker Bacopaside II amplifies inhibition of colon cancer cell migration.

Authors:  Michael L De Ieso; Jinxin V Pei; Saeed Nourmohammadi; Eric Smith; Pak Hin Chow; Mohamad Kourghi; Jennifer E Hardingham; Andrea J Yool
Journal:  Sci Rep       Date:  2019-09-02       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.